Muki Rapp
Technik-/Wissenschafts-/F&E-Leiter bei Notal Vision Ltd.
Aktive Positionen von Muki Rapp
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Notal Vision Ltd.
 Notal Vision Ltd. Medical/Nursing ServicesHealth Services Notal Vision Ltd. develops and manufactures computerized ophthalmic diagnostic devices. It develops age-related macular degeneration (AMD) monitor for patients at risk of vision loss from the devastating effects of wet AMD. The firm provides Preferential Hyperacuity Perimetry, a technology with clinical data for monitoring patients with AMD to eye care professionals. Its products are used for the detection and characterization of central and paracentral metamorphopsia in patients as an aid in monitoring progression of disease factors causing metamorphopsia, such as choroidal neovascularization. The company was founded in 2000 by Barak Azmon and Yair Alster and is headquartered in Tel Aviv, Israel. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Karriereverlauf von Muki Rapp
Ausbildung von Muki Rapp
| The Hebrew University of Jerusalem | Doctorate Degree |
Statistik
International
| Israel | 3 |
Operativ
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
| Graduate Degree | 1 |
Sektoral
| Health Services | 2 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Notal Vision Ltd.
Notal Vision Ltd. Medical/Nursing ServicesHealth Services Notal Vision Ltd. develops and manufactures computerized ophthalmic diagnostic devices. It develops age-related macular degeneration (AMD) monitor for patients at risk of vision loss from the devastating effects of wet AMD. The firm provides Preferential Hyperacuity Perimetry, a technology with clinical data for monitoring patients with AMD to eye care professionals. Its products are used for the detection and characterization of central and paracentral metamorphopsia in patients as an aid in monitoring progression of disease factors causing metamorphopsia, such as choroidal neovascularization. The company was founded in 2000 by Barak Azmon and Yair Alster and is headquartered in Tel Aviv, Israel. | Health Services |
